Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study the investigators aim is to explore the dynamics of (small) intestinal fructose catabolism in humans and ethanol production in relation to small intestinal signalling pathways and changes in pH, using 13C fructose isotope tracing techniques complemented with direct luminal sampling via small intestinal catheter in biopsy proven MASLD/MASH patients vs healthy (BMI<25) subjects. Additionally the investigators will repeat the experiment after four weeks of administering omeprazole at a dose of 40 mg twice daily. Omeprazole is a proton pump inhibitor, known to elevate pH from 2-6.
The investigators will perform a non blinded single centre intervention study in 2x 11 participants
Participants will be either healthy volunteers with a BMI < 25 and Age 18-65 or patients with MASLD with a BMI >25, Age 18-65
The objective of the investigators is to study the fructose host/microbial kinetics in humans and to establish the role of (small) intestinal pH on fructose fermentation and endogenous ethanol production in a MASLD/MASH population versus healthy subjects
Subjects will be given omeprazole orally given twice a day 40mg for four weeks
At baseline and after four weeks of omeprazole, a fructose challenge test with labelled fructose and fomepizole and a gastroscopy will be performed, during which a nasal-intestinal catheter will be placed to allow for luminal sampling during the fructose challenge test.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy volunteer | Active Comparator | healthy volunteers who will get omeprazol daily 2dd40 mg for 4 weeks |
|
| Sujbects with MASLD | Active Comparator | Patients with MASLD who will get omeprazol daily 2dd40 mg for 4 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Omeprazole 40 MG | Drug | Proton pump inhibitor twice a day for 4 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes in ethanol concentrations before and after omeprazol usage | mM (serum, intestinal fluid, urine and feces) | four weeks |
| Changes in fructose concentrations in peripheral blood before and after omeprazol usage | Area under the curve of fructose in peripheral blood upon ingestion of 1 gram / kg unlabeled fructose in combination with 1000mg of D-fructose-13C6 measured during fructose challange test | 4 weeks |
| Changes in fructose metabolites in breath before and after omeprazol usage | Area under the curve of various metabolites (e.g. ethanol) will be measured in breath samples upon ingestion of 1 gram / kg unlabeled fructose in combination with 1000mg of D-fructose-13C6 measured during fructose challange test | 4 weeks |
| Fructose metabolites in feces before and after omeprazol usage | Using 24h feces, the investigators will measure fecal concentrations of fructose metabolites such as ethanol, as well as short chain fatty acids (SCFAs) and bile acids. | 4 weeks |
| Fructose metabolites in urine | Using 24h urine, the investigators will measure fecal concentrations of fructose metabolites such as ethanol, as well as SCFAs and bile acids. | 4 weeks |
| Changes in serum glucose concentrations before and after omeprazol | mmol/l measured during fructose challange test | 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in microbiota composition in luminal samples | changes in relative abundance (%) of bacterial phyla, genera and species between groups and after intervention with omeprazol measured by 16sRNA sequencing and shotgun metagenome analysis | four weeks |
| Changes in dietary intake |
Not provided
Inclusion Criteria:
In case of the healthy subject group:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Max Nieuwdorp, Prof | Contact | 0031 20 5669111 | m.nieuwdorp@amsterdamumc.nl |
| Name | Affiliation | Role |
|---|---|---|
| Max Nieuwdorp, prof | Amsterdam UMC, location AMC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Amsterdam UMC location AMC | Recruiting | Amsterdam | Netherlands |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009853 | Omeprazole |
| ID | Term |
|---|---|
| D053799 | 2-Pyridinylmethylsulfinylbenzimidazoles |
| D013454 | Sulfoxides |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
Not provided
Not provided
2x 11 participants will be given the same intervention (omeprazol daily)
Not provided
Not provided
Not provided
Not provided
Participants are asked to fill out an online dietary questionnaire for the 3 days prior to study visits |
| four weeks |
| Bioreactor analyses | Using specific anaerobic culturing, ethanol production of fecal samples will be assessed of bacterial strains. | four weeks |
| Changes in Oral microbiota composition | changes in relative abundance (%) of bacterial phyla, genera and species between groups and after intervention with omeprazol measured by 16sRNA sequencing. | four weeks |
| Differences in gene expression in small intestinal biopsies | measured by RNA sequencing | 4 weeks |
| Changes in Fecal microbiota composition | changes in relative abundance (%) of bacterial phyla, genera and species between groups and after intervention with omeprazol measured by 16sRNA sequencing and shotgun metagenome analysis | 4 weeks |
| Changes in abundance of post prandial plasma metabolites | Postprandial plasma samples will be prepared for the analysis of mainly: organic acids, amino acids, fatty acids, uric acid, glucose and fructose before and after intervention with omeprazol | 4 weeks |
| D011725 |
| Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |